Jonathan Williams, MD
Infectious Disease · Detroit, MINPI 1760821060
Payments from drug & device makers
What this record shows
This record is dominated by education: $187 of the $187 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Astellas Pharma US Inc. Reporting peaked in 2024 at $80 and has fallen 53.8% since, to $37 in 2025. That places this record below the midpoint for infectious disease clinicians in MI, where the typical reported total is $216.
Across 3 payments — averaging $62.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$187
Across 3 payments — averaging $51,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$110K
- Astrazeneca UK Limited$44K
What the payments were for
- Education$187100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $187 |
How this compares
$187 in reported general payments places this provider in the 45th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 73 | $276,853 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 30 | $114,754 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 22 | $97,726 |
| DescovyEmtricitabine/Tenofov Alafenam | 22 | $46,205 |
| TivicayDolutegravir Sodium | 18 | $45,993 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $31,664 |
| PrezcobixDarunavir/Cobicistat | 12 | $28,967 |
| XeravaEravacycline Di-Hydrochloride | 23 | $17,817 |
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 27 | $15,168 |
| Cefadroxil | 30 | $468 |
| Amikacin Sulfate | 25 | $433 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $237 |
| Montelukast Sodium | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Detroit
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Rodger MacarthurDetroit$150K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Marcus ZervosDetroit$26K
- Jack SobelDetroit$18K
- Smitha GudipatiDetroit$16K
- Ronaldo SupenaDetroit$14K
- Wasif HafeezDetroit$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.